Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DTF20P
|
|||
| Drug Name |
HM71224
|
|||
| Synonyms |
Poseltinib; 1353552-97-2; UNII-D01E4B1U35; D01E4B1U35; LY3337641; N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)furo[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Poseltinib [INN]; GTPL9862; CHEMBL4163691; SCHEMBL14915064; BDBM50369724; BS-15248; HM-71224; LY333764; Example 228 [WO2011162515A2]; HY-109010; CS-0030508; Q27275916; 2-Propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)-; N-(3-((2-(4-(4-Methylpiperazin-1-yl)anilino)furo(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide; N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Rheumatoid arthritis [ICD-11: FA20; ICD-9: 729] | Phase 1 | [1] | |
| Company |
Hanmi Pharmaceutical
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H26N6O3
|
|||
| Canonical SMILES |
CN1CCN(CC1)C2=CC=C(C=C2)NC3=NC4=C(C(=N3)OC5=CC=CC(=C5)NC(=O)C=C)OC=C4
|
|||
| InChI |
1S/C26H26N6O3/c1-3-23(33)27-19-5-4-6-21(17-19)35-25-24-22(11-16-34-24)29-26(30-25)28-18-7-9-20(10-8-18)32-14-12-31(2)13-15-32/h3-11,16-17H,1,12-15H2,2H3,(H,27,33)(H,28,29,30)
|
|||
| InChIKey |
LZMJNVRJMFMYQS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1353552-97-2
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01765478) Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers. U.S. National Institutes of Health. | |||
| REF 2 | HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus. Arthritis Res Ther. 2017 Sep 26;19(1):211. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.